Holen Sie sich die Stockscreener-App
1.19
8.18%
0.09
Handel nachbörslich:
1.19
Schlusskurs vom Vortag:
$1.10
Offen:
$1.15
24-Stunden-Volumen:
6,395
Relative Volume:
0.17
Marktkapitalisierung:
$31.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-3.4186
EPS:
-0.3481
Netto-Cashflow:
-
1W Leistung:
-8.46%
1M Leistung:
+27.00%
6M Leistung:
-60.33%
1J Leistung:
-23.23%
1-Tages-Spanne:
$1.108
$1.2308
1-Wochen-Bereich:
$1.10
$1.2802
52-Wochen-Spanne:
$0.85
$4.40
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Firmenname
Akari Therapeutics Plc Adr
Sektor
Branche
Telefon
(646) 350-0702
Adresse
22 BOSTON WHARF ROAD, BOSTON
Vergleichen Sie AKTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
1.19 | 31.50M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-01-04 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Hochstufung | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Bestätigt | Chardan Capital Markets | Sell |
| 2016-07-11 | Eingeleitet | Chardan Capital Markets | Sell |
Alle ansehen
Akari Therapeutics Plc Adr Aktie (AKTX) Neueste Nachrichten
Akari Therapeutics names new CEO to drive cancer drug innovation - Investing.com India
Akari Therapeutics names new CEO to drive cancer drug innovation By Investing.com - Investing.com South Africa
Ibotta Inc (IBTA) Shares Soar Above 1-Year High - The News Heater
Akari Therapeutics Appoints New CEO, Current CEO to Step Down By Investing.com - Investing.com South Africa
Akari Therapeutics Appoints New CEO, Current CEO to Step Down - Investing.com
Akari Therapeutics secures $7.6 million in private placement - Investing.com India
Major ADC Developer Akari Opens Direct Channel to Investors Through Webull Platform - StockTitan
Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Growth in Short Interest - Defense World
Akari Therapeutics appoints new CEO and board member - Investing.com
Akari Therapeutics names Samir Patel as CEO and adds board member - Investing.com India
Akari Therapeutics Names Interim CEO Patel as Permanent Chief, Adds Jazz Pharma Veteran to Board - StockTitan
Akari Therapeutics appoints new CFO - Investing.com
Akari Therapeutics appoints new CFO By Investing.com - Investing.com South Africa
AKTXAkari Therapeutics plc ADR (0.01 USD) Latest Stock News & Market Updates - StockTitan
Akari Therapeutics Strengthens Leadership: Former CFO Returns After $50M Fundraising Success - StockTitan
Akari Therapeutics Regains Nasdaq Compliance, Secures Market Listing Status | AKTX Stock News - StockTitan
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Benzinga
Akari Therapeutics Completes Peak Bio Merger, Secures $53.2M in Financing Commitments | AKTX Stock News - StockTitan
Akari Therapeutics shareholders approve Peak Bio merger - Investing.com
Akari Therapeutics shareholders approve Peak Bio merger By Investing.com - Investing.com UK
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - StockTitan
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - StockTitan
Akari Therapeutics Plc faces Nasdaq delisting over equity shortfall - Investing.com India
Akari Therapeutics PlcADR (AKTX) Price Target Increased by 45.45% to 81.60 - MSN
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders - StockTitan
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights - StockTitan
Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology - StockTitan
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering - StockTitan
Peak Bio (PKBO) Stock Price, News & Analysis - MarketBeat
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com Australia
Dow Jones News: Dow Rallies 200 Points After Macron and Le Pen Win First Round of French Election - Money Morning
Angion Biomedica (ANGN) Stock Price, News & Analysis - MarketBeat
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN
Finanzdaten der Akari Therapeutics Plc Adr-Aktie (AKTX)
Es liegen keine Finanzdaten für Akari Therapeutics Plc Adr (AKTX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):